# QurAlis Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quralis

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.quralis.com
- Total disclosed funding: $93M
- Latest round: Series B (Dec 20, 2022)
- Investors on record: 15

## About

Based in the US, QurAlis Corporation is a biotechnology company focused on creating precision medicines for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).Founded in 2016 and headquartered in Cambridge, US, QurAlis Corporation is dedicated to developing innovative therapies targeting neurodegenerative disease mechanisms. Kasper Roet, the founder, has a background in the biotech sector, contributing expertise to the company's vision. The company has engaged in 5 deals, with the most recent funding event occurring on December 20, 2022, during a Series B round that raised USD 59.98 mn, led by EQT Life Sciences, alongside numerous prominent investors. The total amount raised by the company stands at USD 59.98 mn with a current valuation of USD 123.87 mn.QurAlis specializes in developing precision medicines aimed at treating neurodegenerative diseases, focusing on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Their proprietary FLEXASO® platform utilizes anti-sense oligonucleotide splice modulation to create therapeutic candidates that target ALS pathology through specific genetic and clinical biomarkers. These therapies are intended for healthcare providers, research institutions, and clinical laboratories in North America and Europe, addressing the urgent need for effective treatments in this field.QurAlis generates revenue through strategic partnerships and collaborations to advance its therapeutic candidates. The company structures agreements around milestone payments and royalties, providing access to its FLEXASO® platform and pipeline therapeutics for partner development. While specific pricing structures are undisclosed, the revenue model involves upfront licensing fees and performance-based payments tied to progress in clinical trials, aligning with its focus on ALS and related diseases.In December 2022, QurAlis Corporation secured USD 59.98 mn in Series B funding, led by EQT Life Sciences, to accelerate the development of its products QRL-201 and QRL-101 for neurological diseases. The company aims to expand its reach into new markets in Europe and North America by 2024, leveraging recent funding to enhance research and development efforts for these upcoming therapies.

## Funding rounds

- Series B, Dec 20, 2022, $60M — Polaris Partners, EQT Life Sciences, Mitsui Global Investment, SV Health Investors, Amgen Ventures, Mission Bay Capital, MP Healthcare Venture Management, Sanofi Ventures, Inkef, Dolby Family Ventures, Mission Biocapital, SUNU Ventures, Droia Ventures, Sanford Biosciences
- Series A, May 1, 2020, $33M — Polaris Partners, Mitsui Global Investment, SV Health Investors, Amgen Ventures, MP Healthcare Venture Management, Inkef, Dolby Family Ventures, Mission Biocapital, Droia Ventures, Sanford Biosciences
- Seed, Nov 19, 2018 — Amgen Ventures, MP Healthcare Venture Management, Mission Biocapital
- Seed, Apr 5, 2018 — Alexandria Venture Investments, Amgen Ventures, MP Healthcare Venture Management

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Seed, Series A, Series B
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Seed, Series A, Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed, Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A, Series B
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A, Series B
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A, Series B
- Sanford Biosciences — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series B